Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1038/s41409-024-02432-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of Dara-VTD induction therapy on stem cell mobilization outcomes in newly diagnosed multiple myeloma patients undergoing autologous stem cell transplantation: a multicenter study.
Ann Hematol
September 2025
Hematology Unit, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Daratumumab combined with bortezomib, thalidomide, and dexamethasone (Dara-VTD) is a highly effective induction therapy for newly diagnosed multiple myeloma (NDMM) patients eligible for autologous stem cell transplantation (ASCT). However, its impact on stem cell mobilization requires a critical evaluation. This study examines the effects of Dara-VTD on stem cell mobilization and collection outcomes.
View Article and Find Full Text PDFThe Impact of Anti-CD38 Monoclonal Antibody Therapy on Stem-Cell Mobilization Yields in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Referred from Community and Academic Oncology Practices: Single Center, Real World Data 2021-2024.
Transplant Cell Ther
August 2025
Division of Blood and Marrow Transplant and Cellular Therapy, Stanford University School of Medicine, Stanford, CA. Electronic address:
Background: Autologous stem cell transplantation (ASCT) remains a standard component of frontline therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). CD38 monoclonal antibodies (mAbs), such as daratumumab and isatuximab, have been incorporated into induction regimens and are associated with deeper responses. However, their impact on hematopoietic stem cell mobilization is unclear, particularly in real-world practice.
View Article and Find Full Text PDFImmunotherapy has transformed the treatment landscape of multiple myeloma (MM), a hematological cancer predominantly affecting older individuals. Yet, whether immune aging, shaped by intrinsic aging processes, genetics and external factors, impacts treatment efficacy remains unclear. To address this, we investigated the influence of age on the immune system in MM patients and explored whether immune aging associates with clinical outcomes in older patients.
View Article and Find Full Text PDFImpact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma.
Blood Cancer J
August 2025
Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elranatamab for Relapsed/Refractory Multiple Myeloma With Severe Renal Impairment Requiring Hemodialysis.
Hematol Oncol
July 2025
Department of Medical Oncology, Inselspital Bern, Bern University Hospital, University of Bern, Bern, Switzerland.
Relapsed/refractory multiple myeloma (RRMM) patients with dialysis-dependent renal impairment face limited therapeutic options due to exclusion from clinical trials, a lack of evidence-based guidelines, and inferior outcomes. Bispecific antibodies targeting B-cell maturation antigen (BCMA) have shown promise in RRMM treatment but remain understudied in this vulnerable population. To illustrate this issue, we introduce the case of a 68-year-old female with triple-class RRMM and end-stage renal disease requiring hemodialysis, treated with elranatamab as a second line treatment following progression after therapy with daratumumab, bortezomib, lenalidomide, and dexamethasone.
View Article and Find Full Text PDF